The agreement with the FDA on a registrational path is a critical regulatory milestone for Protara Therapeutics. It suggests that the company is moving forward with its plans to bring IV Choline Chloride to market, which is likely to be viewed positively by investors. This development reduces regulatory uncertainty and indicates potential future revenue streams from this treatment, thus likely having a positive impact on the stock price in the short term.